Table 2 Characteristics of Four Race-Gender Groups of Primary Care Hypertensive Patients with High Baseline LDL Cholesterol
Characteristic | Black women (N = 1,440) | Black men (N = 666) | White women (N = 661) | White men (N = 717) | P Value |
|---|---|---|---|---|---|
Baseline LDL cholesterol [mg/dl], mean [SD] | 142.8 (29.9) | 138.9 (28.0) | 144.0 (24.3) | 137.2 (23.4) | < 0.001 |
LDL control by 6 months after baseline, % | 16.8 | 18.9 | 20.3 | 28.5 | < 0.001 |
LDL cholesterol tests within 6 months after baseline, N [SD] | 0.85 (0.75) | 0.90 (0.79) | 0.80 (0.77) | 0.92 (0.90) | 0.026 |
Sociodemographic | Â | Â | Â | Â | Â |
Age [years], mean [SD] | 68.4 (9.7) | 61.4 (11.1) | 68.4 (9.9) | 62.3 (10.5) | < 0.001 |
Median income in zipcode of residence, mean $ [SD] | 28,360 (10,904) | 30,692 (12,825) | 57,004 (23,790) | 58,680 (23,464) | < 0.001 |
Insurance type [%] | Â | Â | Â | Â | Â |
   Commercial | 46.4 | 60.7 | 57.5 | 72.5 | < 0.001 |
   Medicaid | 17.4 | 14.9 | 2.0 | 2.2 |  |
   Medicare | 35.4 | 22.8 | 40.2 | 24.8 |  |
   Self pay | 0.8 | 1.7 | 0.3 | 0.4 |  |
LDL Cholesterol | Â | Â | Â | Â | Â |
Baseline LDL [mg/dl], mean [SD] | 142.8 (29.9) | 138.9 (28.0) | 144.0 (24.3) | 137.2 (23.4) | < 0.001 |
LDL tests within 6 months mean [SD] | 0.85 (0.75) | 0.90 (0.79) | 0.80 (0.77) | 0.92 (0.90) | 0.026 |
LDL control by 6 months after baseline, % | 16.8 | 18.9 | 20.3 | 28.5 | < 0.001 |
Clinical | Â | Â | Â | Â | Â |
Vascular disease, % | 30.1 | 28.2 | 21.2 | 21.1 | < 0.001 |
Diabetes, % | 41.5 | 46.2 | 19.5 | 31.1 | < 0.001 |
Renal insufficiency, % | 13.3 | 21.9 | 3.3 | 9.6 | < 0.001 |
Unrelated comorbidities, # | 6.3 | 5.4 | 5.5 | 4.9 | < 0.001 |
Tobacco use, % | Â | Â | Â | Â | Â |
   Current | 11.2 | 14.9 | 5.0 | 10.3 | < 0.001 |
   No | 55.3 | 45.2 | 70.8 | 54.7 |  |
   Not recorded | 33.5 | 39.9 | 24.2 | 35.0 |  |
Lipid-lowering Drug Therapy | Â | Â | Â | Â | |
Treated (%) | 57.4% | 54.7% | 52.5% | 53.7% | 0.134 |
Potency per day of treatment, mean (SD) | 0.96 (0.26) | 0.97 (0.25) | 0.90 (0.25) | 0.91 (0.3) | < 0.001 |
Duration of treatment, days, mean (SD) | 964.5 (550.3) | 919.6 (537.6) | 887.3 (544.9) | 911.7 (548.4) | 0.01 |
Total potency, categorical (treated only) | Â | Â | Â | Â | Â |
   None, % | 42.6 | 45.4 | 47.5 | 46.3 |  |
   Lower [≤840],% | 26.5 | 28.5 | 26.5 | 30.3 | 0.007 |
   Higher [> 840],% | 31.0 | 26.1 | 26.0 | 23.4 |  |
Health Care | Â | Â | Â | Â | Â |
Primary care arrived visits per year, mean (SD) | 6.3 (4.2) | 6.5 (4.6) | 5.8 (3.7) | 5.7 (6.1) | 0.002 |
Kept < 60% of scheduled visits, % | 19.7 | 20.7 | 13.0 | 10.2 | < 0.001 |
Maximum concurrent anti-hypertensive drugs, mean N (SD) | 2.5 (1.3) | 2.3 (1.3) | 1.9 (1.1) | 1.8 (1.2) | < 0.001 |
Provider (N) | Â | Â | Â | Â | Â |
Race, % | Â | Â | Â | Â | Â |
   White (157) | 60.7 | 62.5 | 90.6 | 91.2 | < 0.001 |
   Asian (27) | 11.7 | 7.7 | 3.3 | 2.5 |  |
Other Minority (18) | 27.6 | 30.0 | 6.1 | 6.3 | Â |
   Gender, % |  |  |  |  |  |
Female (110) | 60.3 | 47.3 | 53.7 | 31.3 | < 0.001 |
   Type, % |  |  |  |  |  |
Attending (74) | 56.7 | 61.0 | 69.6 | 73.1 | < 0.001 |
Resident (105) | 17.0 | 16.2 | 7.9 | 8.4 | Â |
Nurse practitioner/Physician assistant (23) | 26.3 | 22.8 | 22.5 | 18.6 | Â |
Annual arrived visits to | 1916.8 | 1980.1 | 2009.0 | 2202.7 | < 0.001 |
provider, mean N (SD) | (1464.7) | (1454.6) | (1207.5) | (1404.4) | Â |